A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors

Öz:

Background/aim: To describe the disease activity and retention rate in rheumatoid arthritis (RA) patients with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or tumor necrosis factor inhibitors (TNFis) who were prescribed tocilizumab (TCZ) as first-line or second-line biologic treatment in real-world setting. Materials and methods: Data gathered from patients’ files was used in a multicenter and retrospective context. Retention rates and the Disease Activity Score in 28 joints with CRP (DAS28-CRP) were evaluated at time points. The relationship of drug efficacy with factors such as smoking, obesity, and previous use of TNFis was also examined. Results: One hundred and twenty-four patients with a median (IQR) RA duration of 3.7 (7.4) years were included. Mean (SD) age was 52.9 (12.9) and 75% of the patients were female. TCZ retention rates in the 6th and 12th months were 94.1% and 86.6%, respectively. In all patients, DAS28-CRP level decreased significantly from baseline to Months 3 and 6. There was an increase in patients with remission and/or low disease activity and a decrease in patients with high disease activity at Month 3 and Month 6 (p < 0.001 for both). Disease activity was similar between subgroups based on body mass index, smoking status, and previous use of TNFis at any time point. Regres- sion analysis showed that absence of concomitant corticosteroid treatment independently was associated with remission/LDA achieve- ment at Month 6 [OR = 0.31, 95% CI (0.14– 0.72), p = 0.006], and Month 12 [OR = 0.35, 95% CI (0.13–0.94), p = 0.037]. Overall, 25 mild adverse events were reported. Conclusion: TCZ was found to be effective and safe in RA patients with IR to csDMARDs and/or TNFis. The drug retention rate was considered satisfactory with more than half of the patients continuing TCZ treatment at Month 12.

Anahtar Kelime: Rheumatoid arthritis anti-interleukin-6 tocilizumab

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 2020; 79 (6): 685- 699. https://doi.org/10.1136/annrheumdis-2019-216655
2. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research 2021; 73 (7): 924-939. https://doi.org/10.1002/acr.24596
3. Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomedical Reports 2013; 1 (2): 177-184. https://doi. org/10.3892/br.2012.42
4. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000; 343 (22): 1586-1593. https://doi.org/10.1056/ NEJM200011303432201
5. Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M et al. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmunity Reviews 2017; 16 (12): 1185-1195. https://doi. org/10.1016/j.autrev.2017.10.002
6. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Design, Development and Therapy 2018; 13: 57-70. https://doi.org/10.2147/DDDT. S150580
7. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 2008; 67 (11): 1516- 1523. https://doi.org/10.1136/ard.2008.092932
8. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis and Rheumatism 2008; 58 (10): 2968-2980. https://doi.org/10.1002/art.23940
9. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371 (9617): 987-997. https://doi.org/10.1016/ S0140-6736(08)60453-5
10. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010; 69 (1): 88-96. https://doi.org/10.1136/ ard.2008.105197
11. Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K et al. Effectiveness of tocilizumab with and without synthetic disease- modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Annals of the Rheumatic Diseases 2016; 75 (7): 1336-1342. https://doi.org/10.1136/ annrheumdis-2015-207760
12. Flipo RM, Maillefert JF, Chazerain P, Idier I, Coudert M et al. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open (Rheumatic & Musculoskeletal Diseases) 2017; 3 (1): e000340. https://doi. org/10.1136/rmdopen-2016-000340
13. Iking-Konert C, von Hinüber U, Richter C, Schwenke H, Gürtler I et al. ROUTINE-a prospective, multicentre, non- interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology (Oxford) 2016; 55 (4): 624-635. https://doi. org/10.1093/rheumatology/kev372
14. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012; 51 Suppl 6: vi5-vi9. https://doi.org/10.1093/rheumatology/kes279
15. Ceriotti F, Henny J, Queraltó J, Ziyu S, Özarda Y et al. Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clinical Chemistry and Laboratory Medicine 2010; 48 (11): 1593-601. https://doi.org/10.1515/CCLM.2010.315
16. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases 2011; 70 (7): 1216-1222. https://doi.org/10.1136/ ard.2010.140129
17. Haraoui B, Casado G, Czirják L, Taylor A, Dong L et al. Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies. Rheumatology and Therapy 2019; 6 (2): 231-243. https://doi.org/10.1007/s40744- 019-0150-x
18. Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scandinavian Journal of Rheumatology 2013; 42 (4): 253-259. https://doi.org/10.3109 /03009742.2012.762037
19. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Annals of the Rheumatic Diseases 2012; 71 (2): 198-205. https://doi.org/10.1136/ard.2010.148700
20. Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM. Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study. Arthritis Care & Research 2017; 69 (10): 1484-1494. https://doi.org/10.1002/acr.23303
21. Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske AE et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clinical Rheumatology 2015; 34 (4): 673-681. https://doi.org/10.1007/ s10067-015-2879-0
22. Best JH, Kuang Y, Jiang Y, Singh R, Karabis A et al. Comparative efficacy (DAS28 remission) of targeted immune modulators for rheumatoid arthritis: a network meta-analysis. Rheumatology and Therapy 2021; 8 (2): 693-710. https://doi.org/10.1007/ s40744-021-00322-y
23. Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Annals of the Rheumatic Diseases 2012; 71 (12): 1950-1954. https://doi. org/10.1136/annrheumdis-2011-201087
24. Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. Clinical Rheumatology 2018; 37 (2): 315-321. https:// doi.org/10.1007/s10067-017-3846-8
25. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis and Rheumatism 1997; 40 (11): 1955-1961. https://doi.org/10.1002/art.1780401106
26. Chang K, Yang SM, Kim SH, Han KH, Park SJ et al. Smoking and rheumatoid arthritis. International Journal of Molecular Sciences 2014; 15 (12): 22279-95. https://doi.org/10.3390/ ijms151222279
27. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care & Research 2013; 65 (1): 94-100. https://doi.org/10.1002/acr.21768
28. Theander E, Proven A, Fallang A, Svelander L, Trollmo T. FRI0163 Smoking status does not seem to affect tocilizumab efficacy in RA patients. Annals of the Rheumatic Diseases 2015; 74: 482. https://doi.org/10.1136/annrheumdis-2015-eular.5909
29. Specker C, Kellner H, Kästner P, Volberg C, Braunewell V et al. AB0396 Tocilizumab iv effectiveness in RA patients is independent of smoking status. Annals of the Rheumatic Diseases 2017; 76: 1187. https://doi.org/10.1136/annrheumdis- 2017-eular.5923
30. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clinical Rheumatology 2016; 35 (4): 857-861. https://doi.org/10.1007/s10067-016-3183-3

APA	Inanc N, terzioglu e, Karabulut Y, YILMAZ Z, Tarhan F, enecik m, sahin a, Küçük A, Ayan A, Ozgen M, KARASU U, Yolbas S (2023). A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. , 731 - 743. 10.55730/1300-0144.5636
Chicago	Inanc Nevsun,terzioglu ender,Karabulut Yusuf,YILMAZ ZEVCET,Tarhan Figen,enecik mehmet emin,sahin ali,Küçük Adem,Ayan Ayse,Ozgen Metin,KARASU UGUR,Yolbas Servet A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. (2023): 731 - 743. 10.55730/1300-0144.5636
MLA	Inanc Nevsun,terzioglu ender,Karabulut Yusuf,YILMAZ ZEVCET,Tarhan Figen,enecik mehmet emin,sahin ali,Küçük Adem,Ayan Ayse,Ozgen Metin,KARASU UGUR,Yolbas Servet A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. , 2023, ss.731 - 743. 10.55730/1300-0144.5636
AMA	Inanc N,terzioglu e,Karabulut Y,YILMAZ Z,Tarhan F,enecik m,sahin a,Küçük A,Ayan A,Ozgen M,KARASU U,Yolbas S A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. . 2023; 731 - 743. 10.55730/1300-0144.5636
Vancouver	Inanc N,terzioglu e,Karabulut Y,YILMAZ Z,Tarhan F,enecik m,sahin a,Küçük A,Ayan A,Ozgen M,KARASU U,Yolbas S A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. . 2023; 731 - 743. 10.55730/1300-0144.5636
IEEE	Inanc N,terzioglu e,Karabulut Y,YILMAZ Z,Tarhan F,enecik m,sahin a,Küçük A,Ayan A,Ozgen M,KARASU U,Yolbas S "A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors." , ss.731 - 743, 2023. 10.55730/1300-0144.5636
ISNAD	Inanc, Nevsun vd. "A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors". (2023), 731-743. https://doi.org/10.55730/1300-0144.5636

APA	Inanc N, terzioglu e, Karabulut Y, YILMAZ Z, Tarhan F, enecik m, sahin a, Küçük A, Ayan A, Ozgen M, KARASU U, Yolbas S (2023). A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. Turkish Journal of Medical Sciences, 53(3), 731 - 743. 10.55730/1300-0144.5636
Chicago	Inanc Nevsun,terzioglu ender,Karabulut Yusuf,YILMAZ ZEVCET,Tarhan Figen,enecik mehmet emin,sahin ali,Küçük Adem,Ayan Ayse,Ozgen Metin,KARASU UGUR,Yolbas Servet A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. Turkish Journal of Medical Sciences 53, no.3 (2023): 731 - 743. 10.55730/1300-0144.5636
MLA	Inanc Nevsun,terzioglu ender,Karabulut Yusuf,YILMAZ ZEVCET,Tarhan Figen,enecik mehmet emin,sahin ali,Küçük Adem,Ayan Ayse,Ozgen Metin,KARASU UGUR,Yolbas Servet A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. Turkish Journal of Medical Sciences, vol.53, no.3, 2023, ss.731 - 743. 10.55730/1300-0144.5636
AMA	Inanc N,terzioglu e,Karabulut Y,YILMAZ Z,Tarhan F,enecik m,sahin a,Küçük A,Ayan A,Ozgen M,KARASU U,Yolbas S A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. Turkish Journal of Medical Sciences. 2023; 53(3): 731 - 743. 10.55730/1300-0144.5636
Vancouver	Inanc N,terzioglu e,Karabulut Y,YILMAZ Z,Tarhan F,enecik m,sahin a,Küçük A,Ayan A,Ozgen M,KARASU U,Yolbas S A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. Turkish Journal of Medical Sciences. 2023; 53(3): 731 - 743. 10.55730/1300-0144.5636
IEEE	Inanc N,terzioglu e,Karabulut Y,YILMAZ Z,Tarhan F,enecik m,sahin a,Küçük A,Ayan A,Ozgen M,KARASU U,Yolbas S "A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors." Turkish Journal of Medical Sciences, 53, ss.731 - 743, 2023. 10.55730/1300-0144.5636
ISNAD	Inanc, Nevsun vd. "A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors". Turkish Journal of Medical Sciences 53/3 (2023), 731-743. https://doi.org/10.55730/1300-0144.5636